Now that The Australian Special Opportunity Fund LP (ASOF) managed by The Lind partners have removed the possibility of a CR and at the same time confirmed the commercial potential of Recce's 327 synthetic antibiotic, it should be all upside from here! I would have preferred a shareholder CR with free attached option, however it is good that The Lind Partners have gotten on-board as they are known for their astute investments in small and mid-cap Biotech companies.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.005(1.52%) |
Mkt cap ! $96.87M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 32.0¢ | $19.12K | 58.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19774 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 6000 | 1 |
View Market Depth
| Last trade - 15.58pm 16/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |